GN
GNTA.US Genenta Science SpA ADR
- Market cap
- USD 47.5M
- P/E
- -
- P/B
- 1.29x
- ROE
- -49.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is GNTA.US undervalued?
Graham numberThe Graham number of Genenta Science SpA ADR cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genenta Science SpA ADR fundamental analysis
No fundamental analysis for Genenta Science SpA ADR yet.
Genenta Science SpA ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genenta Science SpA ADR
Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors. Its activities and acquisition strategy covers aerospace, defense, national security, and biotechnology/biosecurity. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Full company profileGenenta Science SpA ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genenta Science SpA ADR annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | -1.77K | -5.10K | -6.00K | -41.7K | -46.5K | -27.0K | -56.1K |
| Operating Income | -4.56M | -5.20M | -5.93M | -10.8M | -11.5M | -10.2M | -6.34M | -12.8M |
| EBITDA | -4.56M | -5.20M | -5.76M | -8.27M | -11.4M | -9.27M | -5.86M | -10.6M |
| Net Income | -4.53M | -5.20M | -5.76M | -8.28M | -11.4M | -9.31M | -6.27M | -10.7M |
| EPS | -0.25 | -0.29 | -0.32 | -0.45 | -0.63 | -0.51 | -0.32 | -0.51 |
| Balance Sheet | ||||||||
| Total Assets | 21.3M | 17.5M | 40.0M | 33.4M | 22.3M | 14.8M | 31.9M | 31.9M |
| Total Liabilities | 2.50M | 2.35M | 1.17M | 2.30M | 1.91M | 2.33M | 10.0M | 10.0M |
| Shareholders' Equity | 18.9M | 15.2M | 38.9M | 31.1M | 20.4M | 12.5M | 21.8M | 21.8M |
| Cash & Short-term Investments | 20.1M | 15.5M | 37.2M | 29.8M | 18.8M | 12.7M | 28.1M | 28.1M |
| Total Debt | - | - | - | - | 14.59 | 14.6K | 7.60M | 7.60M |
| Cash Flow | ||||||||
| Operating Cash Flow | -2.49M | -6.04M | -6.96M | -7.42M | -11.2M | -6.24M | -6.87M | -6.76M |
| Capital Expenditure | 20.9K | 20.9K | 9.01K | 27.1K | 13.8K | 4.47K | 7.63K | 1.91K |
| Free Cash Flow | -2.49M | -6.07M | -6.97M | -7.45M | -11.2M | -6.24M | -6.88M | -6.76M |
| Ratios | ||||||||
| ROE | -24.0% | -34.3% | -14.8% | -26.6% | -56.0% | -74.5% | -28.7% | -49.1% |
| ROA | -21.2% | -29.7% | -14.4% | -24.8% | -51.2% | -62.8% | -19.7% | -33.7% |
| Debt to Equity | - | - | - | - | 0.00x | 0.00x | 0.35x | 0.35x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genenta Science SpA ADR dividends
Genenta Science SpA ADR has not paid dividends in the last 7 fiscal years.
Who owns Genenta Science SpA ADR
- Insiders 43.49%
- Institutions 4.73%
- Public & others 51.78%
- Shares outstanding 48.2M
- Free float 18.8M
Top funds holding GNTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Eurizon Azioni Internazionali | 360K | 0.75% | 0.00% | Oct 2026 |
| Mediolanum Flessibile Futuro Italia LA | 198K | 0.41% | 0.00% | Jun 2026 |
| QSF - Banor Global Asset Dvrs I EUR Acc | 172K | 0.36% | 0.00% | Sep 2026 |
| Investitori Flessibile | 115K | 0.24% | 0.00% | Sep 2026 |
| Investitori America | 84.8K | 0.18% | 0.00% | Sep 2026 |
| Anthilia Small Cap Italia A | 69.2K | 0.14% | 0.00% | Aug 2026 |
| Kairos Intl SICAV Italia P | 50.2K | 0.10% | 0.00% | Jul 2026 |
| Investitori Longevity A | 34.0K | 0.07% | 0.00% | Sep 2026 |
| Kairos Intl SICAV Made in Italy Y | 12.5K | 0.03% | 0.00% | Jul 2026 |
| Fidelity Nasdaq Composite Index | 6.54K | 0.01% | 0.00% | Aug 2026 |
| LUX IM Global Medtech HX | 16.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding GNTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Eurizon Capital SGR SpA | 360K | 0.75% | 0.00% | Jun 2026 |
| Allianz SE | 234K | 0.49% | 0.00% | Jun 2026 |
| SmartHarvest Portfolios, LLC | 43.9K | 0.09% | -67.38% | Jun 2026 |
| Virtu Financial LLC | 36.9K | 0.08% | 0.00% | Jun 2026 |
| Simplicity Wealth,LLC | 18.6K | 0.04% | +52.24% | Jun 2026 |
| Ground Swell Capital, LLC | 14.4K | 0.03% | 0.00% | Jun 2026 |
| Financial Planning Navigators CORP | 11.4K | 0.02% | 0.00% | Sep 2026 |
| GAMMA Investing LLC | 9.86K | 0.02% | -30.97% | Jun 2026 |
| UBS Group AG | 3.03K | 0.01% | -2.57% | Jun 2026 |
| Independent Advisor Alliance | 0.00 | 0.00% | -100.00% | Jun 2026 |
| AlTi Global Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
| NORGES BANK | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
Genenta Science SpA ADR company profile
- Company name
- Genenta Science SpA ADR
- Ticker
- GNTA.US
- Exchange
- USA Stocks
- Listed since
- Dec 15, 2021
- Sector
- Industrials
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- December
- Address
- Via dell?Annunciata 31, Milan, MI, Italy, 20121
- Phone
- 39 02 29 00 10 55
- Website
- genenta.com
About Genenta Science SpA ADR
Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors. Its activities and acquisition strategy covers aerospace, defense, national security, and biotechnology/biosecurity. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Genenta Science SpA ADR management
4- Mr. Pierluigi ParacchiCo-Founder, Chairman, CEO & GM · born 1973
- Mr. Richard B. SlanskyChief Financial Officer · born 1958
- Mr. Gianfranco De NigrisVice President of Corporate Development
- Ms. Barbara RegoniniFinance Director · born 1973